Brief: Biophytis FY Net Loss At 17.1 Million Euros

Biophytis SA

26/02/2021 09:42

Feb 26 (Reuters) - BIOPHYTIS SA  ALBPS.PA :
    * BIOPHYTIS REPORTS 2020 FULL YEAR RESULTS
    * MAJOR MILESTONES ACHIEVED DURING 2020
    * LAUNCH OF PHASE 2-3 COVA TRIAL ASSESSING SARCONEOS
(BIO101) AS A
POTENTIAL TREATMENT FOR ACUTE RESPIRATORY FAILURE LINKED TO
COVID-19
    * INTERIM ANALYSIS OF PART 1 EXPECTED IN Q1 2021 AND RESULTS
FROM
FULL STUDY (PART 1 AND PART 2) EXPECTED IN Q2 2021
    * TREATMENT COMPLETED FOR LAST PATIENT IN PHASE 2
SARA-INTEREST
TRIAL FOR TREATMENT OF SARCOPENIA. TOP-LINE RESULTS EXPECTED IN
Q2 2021
    * SUCCESSFUL COMPLETION OF FOUR PRIVATE PLACEMENTS,
SIGNIFICANTLY
STRENGTHENING COMPANY FINANCIAL RESOURCES, WITH TOTAL CASH AND
CASH EQUIVALENTS AND OTHER CURRENT FINANCIAL ASSETS AMOUNTING TO
EUR 18.8 MILLION AS OF DECEMBER 31, 2020
    * SUCCESSFUL IPO ON NASDAQ CAPITAL MARKET CLOSED ON FEBRUARY
12,
2021 FOR TOTAL GROSS PROCEEDS OF $20.1 MILLION
    * CASH AND CASH EQUIVALENTS AND OTHER CURRENT FINANCIAL
ASSETS AS
OF DECEMBER 31, 2020 WERE EUR 18.8 MILLION, AN INCREASE OF EUR
12 MILLION COMPARED TO EUR 6.8 MILLION AS OF DECEMBER 31, 2019
    * NET LOSS WAS EUR 17.1 MILLION FOR 2020, AS COMPARED TO EUR
17.8
MILLION FOR 2019
    * FY OPERATING LOSS EUR 13.9 MILLION VERSUS LOSS OF EUR 15.7
MILLION YEAR AGO
    * LAUNCH OF THE PHASE 2-3 COVA TRIAL ASSESSING SARCONEOS
(BIO101):
PATIENT ENROLLMENT FOR PART 1 COMPLETED WITH 50 PATIENTS, AND
TRIAL MOVING TO PART 2 FOLLOWING APPROVALS FROM CERTAIN
REGULATORY AUTHORITIES

Source text for Eikon:  ID:nGNXbF2fqw 
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))